Clostridium difficile is one of the most common hospital acquired infections and in the last decade, there has been a notable increase in the incidence of clostridium difficile infection as well as the severity of the infection owing to recurrence and antibiotic resistance. Disproportionately higher incidence is seen in patients undergoing a long-term antibiotic treatment such as in patients with diseases like COPD and urinary tract infection. A rising prevalence of these diseases would subsequently accelerate the growth of the global clostridium difficile infection treatment market.
Clostridium Difficile Infection Treatment Market contains market size and forecasts of Clostridium Difficile Infection Treatment in Global, including the following market information:
- Global Clostridium Difficile Infection Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Clostridium Difficile Infection Treatment market was valued at 740.8 million in 2021 and is projected to reach US$ 1081.2 million by 2028, at a CAGR of 5.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Clostridium Difficile Infection Treatment include Merck, Baxter International, Sanofi, Pfizer, Novartis, Astellas Pharma, Eli Lilly, AstraZeneca and Actelion Pharmaceuticals and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Clostridium Difficile Infection Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Clostridium Difficile Infection Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Clostridium Difficile Infection Treatment Market Segment Percentages, by Type, 2021 (%)
Global Clostridium Difficile Infection Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Clostridium Difficile Infection Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Sales
Global Clostridium Difficile Infection Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Clostridium Difficile Infection Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Clostridium Difficile Infection Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Clostridium Difficile Infection Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Merck
- Baxter International
- Sanofi
- Pfizer
- Novartis
- Astellas Pharma
- Eli Lilly
- AstraZeneca
- Actelion Pharmaceuticals
- Mylan
Industry Market Size
